Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates an in trans interaction to create a synthetic immune synapse, leads to complex and interconnected rel...
Saved in:
| Main Authors: | Kathryn Ball, Simon J Dovedi, Pavan Vajjah, Alex Phipps |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2181016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults
by: Marcus May, et al.
Published: (2025-08-01) -
Bispecific antibodies: unleashing a new era in oncology treatment
by: Lin Shui, et al.
Published: (2025-08-01) -
In vitro models in drug discovery and development for leishmaniasis: A perspective
by: Simon L. Croft, et al.
Published: (2025-06-01) -
Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term
by: Felix Stader, et al.
Published: (2025-04-01) -
Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens
by: Xirui Xia, et al.
Published: (2025-08-01)